# Landos Biopharma Inc. (LABP)

Source: https://www.quantisnow.com/company/LABP
Generated: 2026-10-30T15:52:54.326Z

- Ticker: LABP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: landosbiopharma.com

## About

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

## Latest LABP news and filings

- 2026-05-05 12:00 UTC [NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD](https://www.quantisnow.com/insight/nimmune-biopharma-announces-presentations-at-digestive-disease-week-2026-supporting-6530895)
- 2026-03-24 12:00 UTC [NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026](https://www.quantisnow.com/insight/nimmune-biopharma-to-present-novel-mechanistic-efficacy-and-translational-data-6466186)
- 2024-06-03 10:04 UTC [SEC Form 15-12G filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-landos-biopharma-inc-5530800)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Callori Fred](https://www.quantisnow.com/insight/sec-form-4-filed-by-callori-fred-5514663)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Mayleben Timothy M](https://www.quantisnow.com/insight/sec-form-4-filed-by-mayleben-timothy-m-5514662)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Girao Tiago](https://www.quantisnow.com/insight/sec-form-4-filed-by-girao-tiago-5514661)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Batycky Alka](https://www.quantisnow.com/insight/sec-form-4-filed-by-batycky-alka-5514660)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Garabedian Christopher Nishan](https://www.quantisnow.com/insight/sec-form-4-filed-by-garabedian-christopher-nishan-5514659)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Adsett Roger](https://www.quantisnow.com/insight/sec-form-4-filed-by-adsett-roger-5514658)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Cataldi Fabio](https://www.quantisnow.com/insight/sec-form-4-filed-by-cataldi-fabio-5514657)
- 2024-05-23 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Oakes Gregory](https://www.quantisnow.com/insight/sec-form-4-filed-by-oakes-gregory-5514656)
- 2024-05-23 20:52 UTC [SEC Form RW filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-landos-biopharma-inc-5514246)
- 2024-05-23 20:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-landos-biopharma-inc-5514229)
- 2024-05-23 20:48 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-landos-biopharma-inc-5514221)
- 2024-05-23 20:47 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-landos-biopharma-inc-5514216)
- 2024-05-23 20:46 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-landos-biopharma-inc-5514214)
- 2024-05-23 20:05 UTC [AbbVie Completes Acquisition of Landos Biopharma](https://www.quantisnow.com/insight/abbvie-completes-acquisition-of-landos-biopharma-5513516)
- 2024-05-23 20:02 UTC [SEC Form 25-NSE filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-landos-biopharma-inc-5513475)
- 2024-05-23 16:12 UTC [SEC Form 8-K] [SEC Form 8-K filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-landos-biopharma-inc-5513040)
- 2024-05-09 12:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-landos-biopharma-inc-5475618)
- 2024-04-26 13:54 UTC [Market Insight] [Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook](https://www.quantisnow.com/insight/ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-5436315)
- 2024-04-25 21:07 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-landos-biopharma-inc-5434719)
- 2024-04-16 19:32 UTC [Leadership Update] [Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie](https://www.quantisnow.com/insight/stockholder-alert-ademi-llp-continues-investigation-of-the-fairness-of-5413101)
- 2024-04-16 12:00 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by Landos Biopharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-landos-biopharma-inc-amendment-5412016)
- 2024-04-15 21:18 UTC [SEC Form PREM14A filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-landos-biopharma-inc-5411215)
- 2024-04-10 20:50 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-landos-biopharma-inc-amendment-5403897)
- 2024-04-10 20:50 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-landos-biopharma-inc-amendment-5403895)
- 2024-04-01 11:12 UTC [Market Chatter] [HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42](https://www.quantisnow.com/insight/hc-wainwright-co-downgrades-landos-biopharma-to-neutral-lowers-price-5378830)
- 2024-03-26 12:50 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-landos-biopharma-inc-5368259)
- 2024-03-25 20:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-landos-biopharma-inc-5366364)
- 2024-03-25 19:00 UTC [Market Insight] [Nasdaq Turns Higher; Akanda Shares Plunge](https://www.quantisnow.com/insight/nasdaq-turns-higher-akanda-shares-plunge-5366287)
- 2024-03-25 18:44 UTC [Market Insight] [Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.quantisnow.com/insight/why-landos-biopharma-shares-are-trading-higher-by-over-170-5366254)
- 2024-03-25 17:30 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-intraday-session-5366153)
- 2024-03-25 15:54 UTC [Market Insight] [Crude Oil Moves Higher; US New Home Sales Fall In February](https://www.quantisnow.com/insight/crude-oil-moves-higher-us-new-home-sales-fall-in-5365969)
- 2024-03-25 15:27 UTC [Market Insight] [Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?](https://www.quantisnow.com/insight/why-is-ulcerative-colitis-focused-landos-biopharma-stock-trading-higher-on-5365923)
- 2024-03-25 14:54 UTC [Market Chatter] [Landos Biopharma shares are trading higher after the company announced that it entered into a definitive agreement to be acquired by AbbVie.](https://www.quantisnow.com/insight/landos-biopharma-shares-are-trading-higher-after-the-company-announced-5365851)
- 2024-03-25 13:42 UTC [Market Insight] [US Stocks Down; Chicago Fed National Activity Index Rises In February](https://www.quantisnow.com/insight/us-stocks-down-chicago-fed-national-activity-index-rises-in-5365713)
- 2024-03-25 13:19 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Landos Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-landos-biopharma-inc-5365667)
- 2024-03-25 13:05 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-pre-market-session-5365626)
- 2024-03-25 12:54 UTC [SEC Form 8-K] [Landos Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/landos-biopharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-5365533)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LABP
- RSS and alerts for LABP: https://www.quantisnow.com/docs/rss-feeds.md